Gilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned_老虎社区_美港股上老虎

Gilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned

Bloomberg2021-08-26

Bristol-Myers patent on immunotherapy invalidated by court Dispute is over revolutionary technique to fight cancer Gilead Sciences Inc. persuaded a U.S. appeals court to reverse a $1.2 billion ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

dzgunners95
·2021-08-26
Lol
回复
4
举报
收起
- mistyzenz:
  Wooom
  2021-08-26
  回复
  举报
- dzgunners95:
  cool
  2021-08-26
  回复
  举报
Jokhang
·2021-08-26
[Miser]
回复
2
举报
收起
- dumdumdum:
  Ok
  2021-08-26
  回复
  举报
- Huatzai:
  Ok
  2021-08-26
  回复
  举报
- Ozalis:
  Yup
  2021-08-26
  回复
  举报
schsch
·2021-08-26
like
回复
6
举报
收起
- Jokhang:
  [Happy]
  2021-08-26
  回复
  举报
- Wins888:
  ok
  2021-08-26
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1143350451?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-08-26 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143350451","market":"us","top_or_hot":-1,"title":"Gilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned","media":"Bloomberg","content":"<div>\n<p>Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique to fight cancer\n\nGilead Sciences Inc. persuaded a U.S. appeals court to reverse a $1.2 billion ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp\">网页链接</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique to fight cancer\n\nGilead Sciences Inc. persuaded a U.S. appeals court to reverse a $1.2 billion ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMY","symbol_name":"施贵宝","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp","article_id":"1143350451","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143350451","pubTimestamp":1629990393,"columns":[],"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique t","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BMY":"施贵宝","GILD":"吉利德科学"},"translate_title":"Gilead获得12亿美元专利损失被Bristol-Myers推翻","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":0.9,"GILD":0.9},"content_text":"Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique to fight cancer\n\nGilead Sciences Inc. persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Inc. had won over revolutionary treatments that use a body’s own immune system to fight cancer.\nThe patent owned by Bristol-Myers’s Juno Therapeutics and the Sloan Kettering Institute for Cancer Research is invalid, the U.S. Court of Appeals for the Federal Circuit ruled. The jury verdict that upheld the patent was “not supported by substantial evidence,” the three-judge panel ruled.\nThe fight was over a pioneering technique known as CAR-T, in which the T cells of a person’s own immune system are modified to attack cancer cells. Gilead’s Kite unit makes Yescarta for the treatment of certain types of large B-cell lymphoma, a blood cancer.\nKite successfully argued that the patent didn’t adequately describe an invention and instead would “cover an enormous number (millions of billions)” of potential candidates. The patent’s “written description contains scant details” of which specific antibody would work, Chief Judge Kimberly Moore wrote for the court.\nA Bristol-Myers spokesperson didn’t immediately comment. Representatives of Gilead didn’t immediately respond to a request for comment.\nImmunotherapy helped spur a takeover bonanza in the drug industry, including Gilead’s $12 billion purchase of Kite in 2017. Juno, which holds the license to the patent at the heart of the trial, wasboughtbyCelgene Corp.for $9 billion in 2018 and Celgene in turn was bought by Bristol-Myers for $74 billion.\nThe dispute started when Juno and Kite were both standalone companies, even before Yescarta went on sale. Bristol-Myers argued that Kite copied a treatment that had been developed by researchers at Memorial Sloan Kettering Cancer Center and licensed to Juno for development of a cancer treatment. Juno and Sloan Kettering filed this lawsuit on the same day that Yescarta received U.S. regulatory approval.\nThe jury initially awarded $585 million in damages plus a 27.6% running royalty on sales of Yescarta. The damage award latergrewto $1.2 billion after enhanced damages.\nThe case is Juno Therapeutics Inc. v. Kite Pharma Inc., U.S. Court of Appeals for the Federal Circuit (Washington).","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":810434579,"gmtCreate":1629991130191,"gmtModify":1704954337349,"author":{"id":"3563319809929304","authorId":"3563319809929304","name":"dzgunners95","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3563319809929304","authorIdStr":"3563319809929304"},"htmlText":"Lol","listText":"Lol","text":"Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/810434579","repostId":1143350451,"repostType":4,"repost":{"id":"1143350451","kind":"news","pubTimestamp":1629990393,"share":"https://www.laohu8.com/m/news/1143350451?lang=&edition=full","pubTime":"2021-08-26 23:06","market":"us","language":"en","title":"Gilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned","url":"https://stock-news.laohu8.com/highlight/detail?id=1143350451","media":"Bloomberg","summary":"Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique t","content":"<ul>\n <li>Bristol-Myers patent on immunotherapy invalidated by court</li>\n <li>Dispute is over revolutionary technique to fight cancer</li>\n</ul>\n<p>Gilead Sciences Inc.&nbsp;persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Inc. had&nbsp;won&nbsp;over revolutionary treatments that use a body’s own immune system to fight cancer.</p>\n<p>The patent owned by&nbsp;Bristol-Myers’s Juno Therapeutics and the&nbsp;Sloan Kettering&nbsp;Institute for Cancer Research is invalid, the U.S. Court of Appeals for the Federal Circuit ruled. The jury verdict that upheld the patent was “not supported by substantial evidence,” the three-judge panel ruled.</p>\n<p>The fight was over a pioneering technique known as CAR-T, in which the T cells of a person’s own immune system are modified to attack cancer cells. Gilead’s Kite unit makes Yescarta for the treatment of certain types of large B-cell lymphoma, a blood cancer.</p>\n<p>Kite successfully argued that the patent didn’t adequately describe an invention and instead would “cover an enormous number (millions of billions)” of potential candidates. The patent’s “written description contains scant details” of which specific antibody would work, Chief Judge Kimberly Moore wrote for the court.</p>\n<p>A Bristol-Myers spokesperson didn’t immediately comment. Representatives of Gilead didn’t immediately respond to a request for comment.</p>\n<p>Immunotherapy helped&nbsp;spur&nbsp;a takeover&nbsp;bonanza&nbsp;in the drug industry, including Gilead’s $12 billion purchase of Kite in 2017. Juno, which holds the license to the patent at the heart of the trial, wasboughtbyCelgene Corp.for $9 billion in 2018 and Celgene in turn was bought by Bristol-Myers for $74 billion.</p>\n<p>The dispute started when Juno and Kite were both standalone companies, even before Yescarta went on sale. Bristol-Myers argued that Kite copied a treatment that had been developed by researchers at Memorial Sloan Kettering Cancer Center and licensed to Juno for development of a cancer treatment. Juno and&nbsp;Sloan Kettering&nbsp;filed this lawsuit on the same day that Yescarta received U.S.&nbsp;regulatory&nbsp;approval.</p>\n<p>The jury initially awarded $585 million in damages plus a 27.6% running royalty on sales of Yescarta. The damage award latergrewto $1.2 billion after enhanced damages.</p>\n<p>The case is&nbsp;Juno Therapeutics Inc.&nbsp;v.&nbsp;Kite Pharma Inc., U.S. Court of Appeals for the Federal Circuit (Washington).</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique to fight cancer\n\nGilead Sciences Inc. persuaded a U.S. appeals court to reverse a $1.2 billion ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","BMY":"施贵宝"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143350451","content_text":"Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique to fight cancer\n\nGilead Sciences Inc. persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Inc. had won over revolutionary treatments that use a body’s own immune system to fight cancer.\nThe patent owned by Bristol-Myers’s Juno Therapeutics and the Sloan Kettering Institute for Cancer Research is invalid, the U.S. Court of Appeals for the Federal Circuit ruled. The jury verdict that upheld the patent was “not supported by substantial evidence,” the three-judge panel ruled.\nThe fight was over a pioneering technique known as CAR-T, in which the T cells of a person’s own immune system are modified to attack cancer cells. Gilead’s Kite unit makes Yescarta for the treatment of certain types of large B-cell lymphoma, a blood cancer.\nKite successfully argued that the patent didn’t adequately describe an invention and instead would “cover an enormous number (millions of billions)” of potential candidates. The patent’s “written description contains scant details” of which specific antibody would work, Chief Judge Kimberly Moore wrote for the court.\nA Bristol-Myers spokesperson didn’t immediately comment. Representatives of Gilead didn’t immediately respond to a request for comment.\nImmunotherapy helped spur a takeover bonanza in the drug industry, including Gilead’s $12 billion purchase of Kite in 2017. Juno, which holds the license to the patent at the heart of the trial, wasboughtbyCelgene Corp.for $9 billion in 2018 and Celgene in turn was bought by Bristol-Myers for $74 billion.\nThe dispute started when Juno and Kite were both standalone companies, even before Yescarta went on sale. Bristol-Myers argued that Kite copied a treatment that had been developed by researchers at Memorial Sloan Kettering Cancer Center and licensed to Juno for development of a cancer treatment. Juno and Sloan Kettering filed this lawsuit on the same day that Yescarta received U.S. regulatory approval.\nThe jury initially awarded $585 million in damages plus a 27.6% running royalty on sales of Yescarta. The damage award latergrewto $1.2 billion after enhanced damages.\nThe case is Juno Therapeutics Inc. v. Kite Pharma Inc., U.S. Court of Appeals for the Federal Circuit (Washington).","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5658061,"gmtCreate":1629991180123,"gmtModify":1631888955829,"authorId":3561962801944040,"author":{"id":3561962801944040,"idStr":"3561962801944040","authorId":3561962801944040,"name":"mistyzenz","avatar":"https://static.tigerbbs.com/b6ce5e71746857498b3364479f136e14","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":810434579,"type":1,"supId":0,"prevId":0,"content":"<u>Wooom</u>","text":"<u>Wooom</u>","html":"<u>Wooom</u>"},{"id":5658059,"gmtCreate":1629991137763,"gmtModify":1631888955817,"authorId":3563319809929304,"author":{"id":3563319809929304,"idStr":"3563319809929304","authorId":3563319809929304,"name":"dzgunners95","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":810434579,"type":1,"supId":0,"prevId":0,"content":"<u>cool</u>","text":"<u>cool</u>","html":"<u>cool</u>"}],"langContent":"EN"},{"id":810432273,"gmtCreate":1629990965992,"gmtModify":1704954334354,"author":{"id":"3586392338558856","authorId":"3586392338558856","name":"Jokhang","avatar":"https://static.tigerbbs.com/d189ae3ec01747be0bd951c14c32cb94","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586392338558856","authorIdStr":"3586392338558856"},"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/810432273","repostId":1143350451,"repostType":4,"repost":{"id":"1143350451","kind":"news","pubTimestamp":1629990393,"share":"https://www.laohu8.com/m/news/1143350451?lang=&edition=full","pubTime":"2021-08-26 23:06","market":"us","language":"en","title":"Gilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned","url":"https://stock-news.laohu8.com/highlight/detail?id=1143350451","media":"Bloomberg","summary":"Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique t","content":"<ul>\n <li>Bristol-Myers patent on immunotherapy invalidated by court</li>\n <li>Dispute is over revolutionary technique to fight cancer</li>\n</ul>\n<p>Gilead Sciences Inc.&nbsp;persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Inc. had&nbsp;won&nbsp;over revolutionary treatments that use a body’s own immune system to fight cancer.</p>\n<p>The patent owned by&nbsp;Bristol-Myers’s Juno Therapeutics and the&nbsp;Sloan Kettering&nbsp;Institute for Cancer Research is invalid, the U.S. Court of Appeals for the Federal Circuit ruled. The jury verdict that upheld the patent was “not supported by substantial evidence,” the three-judge panel ruled.</p>\n<p>The fight was over a pioneering technique known as CAR-T, in which the T cells of a person’s own immune system are modified to attack cancer cells. Gilead’s Kite unit makes Yescarta for the treatment of certain types of large B-cell lymphoma, a blood cancer.</p>\n<p>Kite successfully argued that the patent didn’t adequately describe an invention and instead would “cover an enormous number (millions of billions)” of potential candidates. The patent’s “written description contains scant details” of which specific antibody would work, Chief Judge Kimberly Moore wrote for the court.</p>\n<p>A Bristol-Myers spokesperson didn’t immediately comment. Representatives of Gilead didn’t immediately respond to a request for comment.</p>\n<p>Immunotherapy helped&nbsp;spur&nbsp;a takeover&nbsp;bonanza&nbsp;in the drug industry, including Gilead’s $12 billion purchase of Kite in 2017. Juno, which holds the license to the patent at the heart of the trial, wasboughtbyCelgene Corp.for $9 billion in 2018 and Celgene in turn was bought by Bristol-Myers for $74 billion.</p>\n<p>The dispute started when Juno and Kite were both standalone companies, even before Yescarta went on sale. Bristol-Myers argued that Kite copied a treatment that had been developed by researchers at Memorial Sloan Kettering Cancer Center and licensed to Juno for development of a cancer treatment. Juno and&nbsp;Sloan Kettering&nbsp;filed this lawsuit on the same day that Yescarta received U.S.&nbsp;regulatory&nbsp;approval.</p>\n<p>The jury initially awarded $585 million in damages plus a 27.6% running royalty on sales of Yescarta. The damage award latergrewto $1.2 billion after enhanced damages.</p>\n<p>The case is&nbsp;Juno Therapeutics Inc.&nbsp;v.&nbsp;Kite Pharma Inc., U.S. Court of Appeals for the Federal Circuit (Washington).</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique to fight cancer\n\nGilead Sciences Inc. persuaded a U.S. appeals court to reverse a $1.2 billion ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","BMY":"施贵宝"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143350451","content_text":"Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique to fight cancer\n\nGilead Sciences Inc. persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Inc. had won over revolutionary treatments that use a body’s own immune system to fight cancer.\nThe patent owned by Bristol-Myers’s Juno Therapeutics and the Sloan Kettering Institute for Cancer Research is invalid, the U.S. Court of Appeals for the Federal Circuit ruled. The jury verdict that upheld the patent was “not supported by substantial evidence,” the three-judge panel ruled.\nThe fight was over a pioneering technique known as CAR-T, in which the T cells of a person’s own immune system are modified to attack cancer cells. Gilead’s Kite unit makes Yescarta for the treatment of certain types of large B-cell lymphoma, a blood cancer.\nKite successfully argued that the patent didn’t adequately describe an invention and instead would “cover an enormous number (millions of billions)” of potential candidates. The patent’s “written description contains scant details” of which specific antibody would work, Chief Judge Kimberly Moore wrote for the court.\nA Bristol-Myers spokesperson didn’t immediately comment. Representatives of Gilead didn’t immediately respond to a request for comment.\nImmunotherapy helped spur a takeover bonanza in the drug industry, including Gilead’s $12 billion purchase of Kite in 2017. Juno, which holds the license to the patent at the heart of the trial, wasboughtbyCelgene Corp.for $9 billion in 2018 and Celgene in turn was bought by Bristol-Myers for $74 billion.\nThe dispute started when Juno and Kite were both standalone companies, even before Yescarta went on sale. Bristol-Myers argued that Kite copied a treatment that had been developed by researchers at Memorial Sloan Kettering Cancer Center and licensed to Juno for development of a cancer treatment. Juno and Sloan Kettering filed this lawsuit on the same day that Yescarta received U.S. regulatory approval.\nThe jury initially awarded $585 million in damages plus a 27.6% running royalty on sales of Yescarta. The damage award latergrewto $1.2 billion after enhanced damages.\nThe case is Juno Therapeutics Inc. v. Kite Pharma Inc., U.S. Court of Appeals for the Federal Circuit (Washington).","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5658044,"gmtCreate":1629991001475,"gmtModify":1635138555370,"authorId":3575326657914583,"author":{"id":3575326657914583,"idStr":"3575326657914583","authorId":3575326657914583,"name":"dumdumdum","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":810432273,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"},{"id":5658103,"gmtCreate":1629991608129,"gmtModify":1635138550089,"authorId":3576616245100549,"author":{"id":3576616245100549,"idStr":"3576616245100549","authorId":3576616245100549,"name":"Huatzai","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":810432273,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5658287,"gmtCreate":1629993076923,"gmtModify":1635138536243,"authorId":3560605092408880,"author":{"id":3560605092408880,"idStr":"3560605092408880","authorId":3560605092408880,"name":"Ozalis","avatar":"https://static.tigerbbs.com/8fd60f6aec9bcf42c1aad6b3b77ba379","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":810432273,"type":1,"supId":0,"prevId":0,"content":"Yup","text":"Yup","html":"Yup"}],"langContent":"EN"},{"id":810497117,"gmtCreate":1629990424839,"gmtModify":1704954322726,"author":{"id":"3575927670533252","authorId":"3575927670533252","name":"schsch","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575927670533252","authorIdStr":"3575927670533252"},"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/810497117","repostId":1143350451,"repostType":4,"repost":{"id":"1143350451","kind":"news","pubTimestamp":1629990393,"share":"https://www.laohu8.com/m/news/1143350451?lang=&edition=full","pubTime":"2021-08-26 23:06","market":"us","language":"en","title":"Gilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned","url":"https://stock-news.laohu8.com/highlight/detail?id=1143350451","media":"Bloomberg","summary":"Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique t","content":"<ul>\n <li>Bristol-Myers patent on immunotherapy invalidated by court</li>\n <li>Dispute is over revolutionary technique to fight cancer</li>\n</ul>\n<p>Gilead Sciences Inc.&nbsp;persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Inc. had&nbsp;won&nbsp;over revolutionary treatments that use a body’s own immune system to fight cancer.</p>\n<p>The patent owned by&nbsp;Bristol-Myers’s Juno Therapeutics and the&nbsp;Sloan Kettering&nbsp;Institute for Cancer Research is invalid, the U.S. Court of Appeals for the Federal Circuit ruled. The jury verdict that upheld the patent was “not supported by substantial evidence,” the three-judge panel ruled.</p>\n<p>The fight was over a pioneering technique known as CAR-T, in which the T cells of a person’s own immune system are modified to attack cancer cells. Gilead’s Kite unit makes Yescarta for the treatment of certain types of large B-cell lymphoma, a blood cancer.</p>\n<p>Kite successfully argued that the patent didn’t adequately describe an invention and instead would “cover an enormous number (millions of billions)” of potential candidates. The patent’s “written description contains scant details” of which specific antibody would work, Chief Judge Kimberly Moore wrote for the court.</p>\n<p>A Bristol-Myers spokesperson didn’t immediately comment. Representatives of Gilead didn’t immediately respond to a request for comment.</p>\n<p>Immunotherapy helped&nbsp;spur&nbsp;a takeover&nbsp;bonanza&nbsp;in the drug industry, including Gilead’s $12 billion purchase of Kite in 2017. Juno, which holds the license to the patent at the heart of the trial, wasboughtbyCelgene Corp.for $9 billion in 2018 and Celgene in turn was bought by Bristol-Myers for $74 billion.</p>\n<p>The dispute started when Juno and Kite were both standalone companies, even before Yescarta went on sale. Bristol-Myers argued that Kite copied a treatment that had been developed by researchers at Memorial Sloan Kettering Cancer Center and licensed to Juno for development of a cancer treatment. Juno and&nbsp;Sloan Kettering&nbsp;filed this lawsuit on the same day that Yescarta received U.S.&nbsp;regulatory&nbsp;approval.</p>\n<p>The jury initially awarded $585 million in damages plus a 27.6% running royalty on sales of Yescarta. The damage award latergrewto $1.2 billion after enhanced damages.</p>\n<p>The case is&nbsp;Juno Therapeutics Inc.&nbsp;v.&nbsp;Kite Pharma Inc., U.S. Court of Appeals for the Federal Circuit (Washington).</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique to fight cancer\n\nGilead Sciences Inc. persuaded a U.S. appeals court to reverse a $1.2 billion ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","BMY":"施贵宝"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143350451","content_text":"Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique to fight cancer\n\nGilead Sciences Inc. persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Inc. had won over revolutionary treatments that use a body’s own immune system to fight cancer.\nThe patent owned by Bristol-Myers’s Juno Therapeutics and the Sloan Kettering Institute for Cancer Research is invalid, the U.S. Court of Appeals for the Federal Circuit ruled. The jury verdict that upheld the patent was “not supported by substantial evidence,” the three-judge panel ruled.\nThe fight was over a pioneering technique known as CAR-T, in which the T cells of a person’s own immune system are modified to attack cancer cells. Gilead’s Kite unit makes Yescarta for the treatment of certain types of large B-cell lymphoma, a blood cancer.\nKite successfully argued that the patent didn’t adequately describe an invention and instead would “cover an enormous number (millions of billions)” of potential candidates. The patent’s “written description contains scant details” of which specific antibody would work, Chief Judge Kimberly Moore wrote for the court.\nA Bristol-Myers spokesperson didn’t immediately comment. Representatives of Gilead didn’t immediately respond to a request for comment.\nImmunotherapy helped spur a takeover bonanza in the drug industry, including Gilead’s $12 billion purchase of Kite in 2017. Juno, which holds the license to the patent at the heart of the trial, wasboughtbyCelgene Corp.for $9 billion in 2018 and Celgene in turn was bought by Bristol-Myers for $74 billion.\nThe dispute started when Juno and Kite were both standalone companies, even before Yescarta went on sale. Bristol-Myers argued that Kite copied a treatment that had been developed by researchers at Memorial Sloan Kettering Cancer Center and licensed to Juno for development of a cancer treatment. Juno and Sloan Kettering filed this lawsuit on the same day that Yescarta received U.S. regulatory approval.\nThe jury initially awarded $585 million in damages plus a 27.6% running royalty on sales of Yescarta. The damage award latergrewto $1.2 billion after enhanced damages.\nThe case is Juno Therapeutics Inc. v. Kite Pharma Inc., U.S. Court of Appeals for the Federal Circuit (Washington).","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5658039,"gmtCreate":1629990959365,"gmtModify":1631889100359,"authorId":3586392338558856,"author":{"id":3586392338558856,"idStr":"3586392338558856","authorId":3586392338558856,"name":"Jokhang","avatar":"https://static.tigerbbs.com/d189ae3ec01747be0bd951c14c32cb94","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":810497117,"type":1,"supId":0,"prevId":0,"content":"[Happy]","text":"[Happy]","html":"[Happy]"},{"id":5657980,"gmtCreate":1629990529601,"gmtModify":1631889100346,"authorId":3573623994106312,"author":{"id":3573623994106312,"idStr":"3573623994106312","authorId":3573623994106312,"name":"Wins888","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":810497117,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":38,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}